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Abstract
Background: Autosomal recessive juvenile parkinsonism (AR-JP) is caused by mutations in the
parkin gene which encodes an E3 ubiquitin-protein ligase. Parkin is thought to be critical for
protecting dopaminergic neurons from toxic insults by targeting misfolded or oxidatively damaged
proteins for proteasomal degradation. Surprisingly, mice with targeted deletions of parkin do not
recapitulate robust behavioral or pathological signs of parkinsonism. Since Parkin is thought to
protect against neurotoxic insults, we hypothesized that the reason Parkin-deficient mice do not
develop parkinsonism is because they are not exposed to appropriate environmental triggers. To
test this possibility, we challenged Parkin-deficient mice with neurotoxic regimens of either
methamphetamine (METH) or 6-hydroxydopamine (6-OHDA). Because Parkin function has been
linked to many of the pathways involved in METH and 6-OHDA toxicity, we predicted that Parkin-
deficient mice would be more sensitive to the neurotoxic effects of these agents.
Results:  We found no signs consistent with oxidative stress, ubiquitin dysfunction, or
degeneration of striatal dopamine neuron terminals in aged Parkin-deficient mice. Moreover,
results from behavioral, neurochemical, and immunoblot analyses indicate that Parkin-deficient
mice are not more sensitive to dopaminergic neurotoxicity following treatment with METH or 6-
OHDA.
Conclusion: Our results suggest that the absence of a robust parkinsonian phenotype in Parkin-
deficient mice is not due to the lack of exposure to environmental triggers with mechanisms of
action similar to METH or 6-OHDA. Nevertheless, Parkin-deficient mice could be more sensitive
to other neurotoxins, such as rotenone or MPTP, which have different mechanisms of action;
therefore, identifying conditions that precipitate parkinsonism specifically in Parkin-deficient mice
would increase the utility of this model and could provide insight into the mechanism of AR-JP.
Alternatively, it remains possible that the absence of parkinsonism in Parkin-deficient mice could
reflect fundamental differences between the function of human and mouse Parkin, or the existence
of a redundant E3 ubiquitin-protein ligase in mouse that is not found in humans. Therefore,
additional studies are necessary to understand why Parkin-deficient mice do not display robust
signs of parkinsonism.
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Background
Parkinson's disease (PD) is a common neurological disor-
der that leads to severe motor disabilities due to degener-
ation of dopaminergic neurons in the substantia nigra
pars compacta. Although it remains unclear how or why
these specific neurons degenerate, the mechanisms likely
depend on both environmental and genetic factors.
Epidemiological studies suggest that exposure to certain
environmental factors, such as pesticides, well water,
heavy metals, solvents, or carbon monoxide, significantly
increase the risk of developing PD [1-4]. These environ-
mental factors are thought to inhibit mitochondrial func-
tion, increase oxidative stress, damage proteins, and
inhibit ubiquitin-proteasome system (UPS) function in
dopamine neurons [5].
Genetic studies have determined that mutations in the
human parkin gene can cause AR-JP, a PD-like disorder
[6]. The Parkin protein is a widely expressed, E3 ubiqui-
tin-protein ligase that is thought to target proteins, possi-
bly those oxidatively damaged from environmental
insults, for proteasomal degradation [6-8]. In the absence
of Parkin function, oxidatively damaged proteins may not
be cleared by the cell [9], and these proteins could in turn
propagate damage to additional proteins [10]. Parkin may
also be involved in the unfolded protein response (UPR)
to endoplasmic reticulum (ER) stress [8,11] or in main-
taining mitochondrial function [12,13]. Dysfunction in
either of these pathways as a result of parkin mutations
could also cause oxidative stress and cell death [14,15].
Understanding how mutations in parkin  lead to
dopamine neuron cell death could provide insight into
the mechanism and treatment of other PD-like disorders.
To investigate how mutations in parkin lead to parkinson-
ism, several lines of mice with a targeted disruption of the
mouse parkin gene, Park2, have been generated. Given the
overwhelming evidence that mutations in parkin  cause
AR-JP in humans, it is surprising that mice with targeted
deletions of parkin do not develop robust behavioral or
pathological signs of parkinsonism [16-19]. These find-
ings suggest that loss of Parkin function may not be suffi-
cient for dopamine neuron degeneration in mice.
Consistent with this idea, the age of onset, disease pro-
gression, and symptom severity can differ between AR-JP
patients with similar parkin  mutations, suggesting that
environmental factors may contribute to the pathogenesis
[20-22]. Since Parkin is thought to protect against neuro-
toxic insults [23], we hypothesized that the reason Parkin-
deficient mice do not develop parkinsonism is because
they are not exposed to appropriate environmental stress.
In this study, we extended our initial characterization
study [16] by specifically investigating whether aged Par-
kin-deficient mice exhibit signs of ubiquitin dysregula-
tion, increased oxidative damage to proteins, or
dopamine terminal degeneration consistent with Parkin's
proposed function in humans. We also evaluated whether
Parkin-deficient mice are more sensitive to nigrostriatal
injury following treatment with the neurotoxins 6-OHDA
or METH.
6-OHDA is a hydroxylated dopamine analogue that is
readily oxidized causing ROS-mediated damage [24],
mitochondrial dysfunction [25], ER stress, activation of
the UPR [26,27], and an increase in ubiquitin-mediated
protein degradation [28]. Some of these effects are likely
mediated by iron-dependent mechanisms [29,30]. More-
over, 6-OHDA toxicity is exacerbated by ubiquitin-protea-
some system dysfunction [28], and Parkin-overexpression
in cell culture can protect against 6-OHDA toxicity [31].
METH is a drug of abuse that releases vesicular dopamine
into the cytoplasm and extracellular space [32]. The dis-
placed dopamine can be readily oxidized [33] and may
underlie the observed increases in hydroxyl radical levels
[34], oxidatively damaged proteins [35], and endogenous
formation of 6-OHDA [36] following METH treatment.
METH neurotoxicity can inhibit mitochondrial function
[37,38] and can be modified by alterations in mitochon-
drial function [39,40]. Moreover, METH toxicity involves
autophagy [41], resembles ubiquitin-proteasome system
dysfunction [42], and can activate ER stress and mito-
chondrial cell-death pathways [43]. There is also evidence
that METH toxicity is partially mediated by glutamate
[44,45].
Because Parkin function has been linked to many of the
pathways involved in METH and 6-OHDA toxicity, we
predicted that Parkin-deficient mice would be more sensi-
tive to the neurotoxic effects of these agents.
Results
Aged Parkin-deficient mice do not exhibit signs consistent 
with ubiquitin dysfunction, oxidative stress, or dopamine 
neuron terminal degeneration
We predicted that the absence of Parkin in mice would
lead to dysregulation of total ubiquitin levels; however,
there was no difference between aged, 22-month-old
wild-type control mice (WT) and Parkin-deficient mice
(KO) using immunoblot analysis of striatal or cortical tis-
sue (Table 1). We also hypothesized that Parkin-deficient
mice would exhibit an accumulation of oxidized proteins.
Oxidation of proteins by reactive oxygen species and other
reactive species, such as 4-hydroxy-2-nonenal from lipid
peroxidation, produces protein carbonyl derivates [46].
Protein carbonyl levels have been extensively used as a
sensitive marker for oxidative stress in various model sys-
tems [46], and patients with PD exhibit a general increaseBMC Neuroscience 2005, 6:71 http://www.biomedcentral.com/1471-2202/6/71
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in protein carbonyls [47]. Using immunoblot analysis, we
detected no differences in the levels of striatal or cortical
protein carbonyls between aged WT and KO mice (Table
1). To evaluate dopamine neuron terminal integrity in
Parkin-deficient mice, we performed immunoblot analy-
sis of striatal dopamine transporter (DAT) levels. No dif-
ference between WT and KO mice was detected (Table 1).
Parkin-deficient mice are not more sensitive to 6-OHDA 
toxicity
To determine whether Parkin-deficient mice are more sen-
sitive to the neurotoxin 6-OHDA, we treated 3-month-old
WT and KO mice with a unilateral, intrastriatal injection
of saline (SAL) or 6-OHDA. Mice were treated with either
a 4 µg or 8 µg dose of 6-OHDA because our objective was
to find a dose that would cause mild neurotoxicity in WT
mice but severe neurotoxicity in KO mice.
Beginning 14 days after surgery, analyses of apomorphine
(APO)- and amphetamine (AMPH)- induced rotational
behaviors were conducted to evaluate the consequences of
6-OHDA neurotoxicity [48]. Mice were first challenged
with the postsynaptic dopamine receptor agonist APO.
Rotations away from the lesioned side (contralateral)
reflect postsynaptic dopamine receptor supersensitivity
following striatal dopamine depletion [49,50]. Repeated
measures ANOVAs were used to compare the number of
net rotations following a subcutaneous injection of SAL
versus APO. There was no significant effect of APO on
rotational behavior in mice that received an intrastriatal
injection of SAL; however, mice treated with 4 or 8 µg 6-
OHDA demonstrated significant contralateral rotations (4
µg 6-OHDA, F1,22 = 4.6, p = 0.04; 8 µg 6-OHDA, F1,14 =
12.7, p = 0.003). Moreover, there was a dose-dependent
effect of 6-OHDA on rotational behavior; mice treated
with 8 µg 6-OHDA exhibited significantly greater contral-
ateral rotations compared to mice treated with 4 µg 6-
OHDA (APO Treatment × 6-OHDA Treatment interac-
tion, F1,36 = 8.7, p = 0.006). However, there was no differ-
ence in APO-induced rotational behavior between WT
and KO mice treated with SAL or either dose of 6-OHDA
(Fig. 1A; Genotype × APO Treatment interaction: 4 µg 6-
OHDA, F1,22 = 1.5, p = 0.24; 8 µg 6-OHDA, F1,14 = 0.2, p =
0.65).
Fifteen days after surgery, mice were challenged with
AMPH to evaluate rotational behavior. Because AMPH
causes presynaptic dopamine release, rotations towards
the lesioned side (ipsilateral) reflect loss of striatal
dopamine terminals [49,50]. AMPH had no effect on rota-
tional behavior in mice that received an intrastriatal injec-
tion of SAL (F1,10 = 2.9, p = 0.12). Mice that received 4 or
8 µg 6-OHDA demonstrated significant ipsilateral rota-
tions following AMPH treatment (4 µg 6-OHDA, F1,22 =
5.8, p = 0.02; 8 µg 6-OHDA, F1,14 = 16.9, p = 0.001); how-
ever, a dose-dependent effect of 6-OHDA on AMPH-
induced rotations was not observed. There was no differ-
ence between WT and KO mice in AMPH-induced rota-
tional behavior at either dose (Fig. 1B; Genotype × AMPH
Treatment interaction: 4 µg 6-OHDA, F1,22 = 0.5, p = 0.49;
8 µg 6-OHDA, F1,14 = 0.0, p = 0.93).
Eighteen days after surgery, striatal samples from the
injected and uninjected sides were collected for neuro-
chemical analyses to determine the concentrations of the
neurotransmitters norepinephrine (NE), dopamine, and
serotonin (5-HT); the dopamine-related metabolites 3-
methoxytyramine (3-MT), 3,4-dihydroxyphenylacetic
acid (DOPAC), and homovanillic acid (HVA); and the 5-
HT-related metabolite 5-hydroxyindoleacetic acid (5-
HIAA). For each animal, data from the treated (injected)
striatum was compared to data from the untreated stria-
tum using repeated measures ANOVAs. Intrastriatal injec-
tion of SAL had no effect on dopamine levels (F1,10 = 0.0,
p = 0.95) or any other neurochemicals measured (3-MT,
DOPAC, HVA, NE, 5-HT, 5-HIAA). Treatment with 4 µg or
8 µg 6-OHDA led to a ~40% reduction in dopamine levels
(4 µg 6-OHDA, F1,22 = 24.0, p < 0.0001; 8 µg 6-OHDA,
F1,14 = 14.8, p = 0.002); however, there was no difference
between WT and KO mice at either dose (Fig. 1C; Geno-
type × 6-OHDA Treatment interaction: 4 µg 6-OHDA,
F1,22 = 0.1, p = 0.78; 8 µg 6-OHDA, F1,14 = 0.7, p = 0.41).
Although treatment with 8 µg 6-OHDA led to more APO-
induced rotational behavior compared to 4 µg 6-OHDA,
it did not produce a significantly greater dopamine deple-
tion (F1,36 = 0.4, p  = 0.54). Significant reductions in
DOPAC, HVA, 3-MT, and dopamine/DOPAC were
observed in striata treated with 6-OHDA; Genotype had
no effect on these decreases (data not shown). 5-HT or 5-
Table 1: Immunoblot analyses of aged Parkin-deficient mouse brains. Data are expressed as mean ± SEM in arbitrary units after 
normalization to WT levels.
Immunoblot Region WT (N = 6) KO (N = 6)
Protein carbonyl Striatum 100 ± 5 100 ± 13
Cortex 100 ± 8 89 ± 7
Ubiquitin Striatum 100 ± 9 95 ± 7
Cortex 100 ± 8 98 ± 7
DAT Striatum 100 ± 4 99 ± 8BMC Neuroscience 2005, 6:71 http://www.biomedcentral.com/1471-2202/6/71
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HIAA levels were not reduced on the 6-OHDA-lesioned
side, but there was a trend towards decreased NE on the
lesioned side with no effect of Genotype (data not
shown).
Parkin-deficient mice are not more sensitive to METH 
toxicity
To determine whether Parkin-deficient mice are more sen-
sitive to the neurotoxin METH, 3-month-old WT and KO
Parkin deficient-mice are not more sensitive to 6-OHDA toxicity Figure 1
Parkin deficient-mice are not more sensitive to 6-OHDA toxicity. A. WT mice (filled square symbols) and KO mice 
(open circle symbols) treated with 4 µg 6-OHDA or 8 µg 6-OHDA displayed similar contralateral, rotational behavior 
(expressed as net negative rotations) following APO-treatment. B. Ipsilateral rotational behavior (expressed as net positive 
rotations) following AMPH treatment was also indistinguishable between WT and KO mice. C. There was no difference 
between WT and KO mice in striatal dopamine (DA) levels (expressed as ng/mg protein) on the intact, uninjected side versus 
the side treated with SAL, 4 µg 6-OHDA, or 8 µg 6-OHDA. The numbers of mice used for each genotype are indicated in A; 
these same mice were also analyzed in B and C. Data are expressed as mean ± SEM.
Intact Injected
0
25
50
75
100
125
Intact Injected Intact Injected
SAL APO
-100
-80
-60
-40
-20
0
20
40
60
80
100
SAL APO SAL APO
SAL AMPH
-60
-40
-20
0
20
40
60
SAL AMPH SAL AMPH
A
B
C
SAL 4 µg 6-OHDA 8 µg 6-OHDA
D
A
R
o
t
a
t
i
o
n
s
R
o
t
a
t
i
o
n
s
WT
N=6
KO
N=6
N=10
N=14
N=8
N=8BMC Neuroscience 2005, 6:71 http://www.biomedcentral.com/1471-2202/6/71
Page 5 of 10
(page number not for citation purposes)
mice were treated with repeated, acute administration of
SAL or METH. Mice received either a low (2.5 mg/kg body
weight) or moderate dose (5.0 mg/kg body weight) of
METH because our objective was to find a dose that would
cause mild neurotoxicity in WT mice but severe neurotox-
icity in KO mice.
We have previously demonstrated that KO mice have a
normal hyperlocomotor response to repeated administra-
tion of AMPH (4.0 mg/kg body weight), a psychostimu-
lant similar to METH [16]. Because METH neurotoxicity
can be modified by decreasing METH-induced hyperther-
mia [51], differences between WT and KO mice in body
temperature regulation would confound interpretation of
results. Body temperature regulation over 24 hr and in
response to a cold challenge is indistinguishable between
aged WT and KO mice; moreover, there are no differences
in body temperature between 3-month-old WT and KO
mice [16]. In the present study, we monitored body tem-
perature before and during METH treatment in WT and
KO mice. Treatment with METH at 5.0 mg/kg led to a sig-
nificantly greater METH-induced hyperthermia compared
to treatment with 2.5 mg/kg (Dose effect, F1,29 = 7.1, p =
0.01); however, there were no significant body tempera-
ture differences between WT and KO mice following
METH treatment (Fig. 2A, 2B; Genotype effect, F1,29 = 0.3,
p = 0.56; Genotype × Dose interaction, F1,29 = 2.4, p =
0.13). The mean body weight among all 3-month-old WT
and KO mice used for this study was not different (WT =
32.0 ± 0.4 g, N = 47; KO = 31.7 ± 0.5 g, N = 57; Student t-
test, p = 0.69).
Seven days following treatment, METH neurotoxicity was
evaluated by neurochemical and immunoblot analyses.
Parkin-deficient mice are not more sensitive to METH toxicity Figure 2
Parkin-deficient mice are not more sensitive to METH toxicity. The hyperthermic response to METH treatment at 
A. 2.5 mg/kg and B. 5.0 mg/kg was indistinguishable between WT (filled square symbols) and KO (open circle symbols) mice. 
Body temperature (°C) was measured before METH treatment (time = 0 hr) and every hour thereafter. C. There was no dif-
ference between WT and KO mice in the depletion of striatal dopamine (DA) levels (expressed as ng/mg protein) following 
METH treatment. D. There was also no difference in the reduction of striatal DAT levels following METH treatment (data are 
expressed in arbitrary units after normalization to WT levels). The numbers of mice used for each genotype are indicated in 
the figure. Data are expressed as mean ± SEM.
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There was a significant reduction in striatal dopamine lev-
els following METH treatment (Treatment effect, F2,46 =
45.4, p < 0.0001). Treatment with METH at 5.0 mg/kg pro-
duced a significantly greater dopamine depletion com-
pared to 2.5 mg/kg (80% versus 50% dopamine
reduction; F1,32 = 30.0, p < 0.0001). However, we detected
no difference between genotypes in the magnitude of
dopamine depletion following METH treatment (Fig. 2C;
Genotype effect, F1,46 = 0.9, p = 0.34; Genotype × Treat-
ment interaction, F2,46 = 0.2, p = 0.86). We also observed
significant reductions in the dopamine metabolites
DOPAC, HVA, and 3-MT following METH treatment, but
there were no differences between genotypes in these
reductions (data not shown). Reductions in striatal NE, 5-
HT, or 5-HIAA were not detected (data not shown).
Immunoblot analysis of striatal DAT levels, a marker for
dopamine neuron terminal integrity, demonstrated a
30% reduction following treatment with METH (2.5 mg/
kg; Treatment effect, F1,20 = 10.3, p = 0.004); however,
there was no difference between WT and KO mice (Fig.
2D; Genotype × Treatment interaction, F1,20 = 1.6, p  =
0.22).
Discussion
We expected Parkin-deficient mice to demonstrate
increased signs of oxidized proteins as a result of increased
pro-oxidant activity, for example due to mitochondrial
dysfunction; decreased antioxidant activity, for example
due to dysregulation of glutathione levels; or decreased
protein clearance due to dysfunction of the ubiquitin pro-
teasome system. Previous studies have identified
increased protein carbonyls in the brains of Parkin-defi-
cient mice [13], a slight increase in GSH levels specifically
in the striatum, and an increase in DOPAC/3-MT levels
consistent with a shift towards dopamine metabolism by
the H2O2-producing monoamine oxidase pathway [18]. A
slight reduction in striatal DAT levels was also previously
observed, which may reflect initial damage to dopamine
neuron terminals [18]. In this study, Parkin-deficient mice
did not exhibit increased levels of protein carbonyls, and
consistent with our previous report using aged mice [16],
we found no difference in DOPAC/3-MT levels between
young WT and KO mice (data not shown). Moreover, lev-
els of total ubiquitin and striatal DAT in aged Parkin-defi-
cient mice were indistinguishable from WT mice. Our
results suggest that loss of Parkin in mice does not lead to
robust oxidative stress, ubiquitin dysfunction, or
dopamine neuron terminal degeneration. Nevertheless,
we cannot rule out the possibility that differences in oxi-
dation between WT and KO mice are limited to a few spe-
cific proteins [52].
The current study extends the number of inconsistent
findings reported in several Parkin-deficient mouse mod-
els [13,16-19]. Reasons for discrepancies among these
Parkin-deficient mouse models have been previously dis-
cussed and include differences in experimental technique,
differences in genetic background, differences in the gene
targeting strategy, or confounds of gene targeting [16]. Of
biological significance, the type of targeted mutation in
these mouse models could differentially affect expression
of potential Parkin isoforms with unique functions [53-
55]. Parkin-deficient mice used in this study lack exon 2,
which encodes most of the ubiquitin-like domain
believed to be required for interacting with the proteas-
ome [56] and ubiquitinated substrates [57].
Interpretation of studies using Parkin-deficient mice can
be complicated because a mixed B6;129 genetic back-
ground was used in this study and most previous studies;
therefore, many genes linked to parkin will be 129 derived
in KO mice and B6 derived in WT mice [16]. Even after 12
backcrosses to the B6 genetic background, ~16 cM sur-
rounding the mutant parkin  allele could remain 129
derived; however, in control mice the corresponding
region will likely remain B6 derived [58,59]. It is possible
that the increased oxidative stress and protein carbonyls
previously reported in Parkin-deficient mice are not due
to the parkin  mutation but reflect strain differences
between WT and KO mice in these closely linked genes.
For example, mitochondrial superoxide dismutase 2 (Sod2),
which is tightly linked to parkin (~2 cM [60]), is involved
in mitochondrial function and protects against oxidative
stress.  Sod2  polymorphisms between inbred mouse
strains have been described and can lead to a reduction in
specific activity of the protein and an increase in protein
carbonyls [61,62]. It is very likely that the Sod2 gene will
differ between Parkin-deficient and control mice unless
appropriate breeding strategies are employed.
Despite the inconsistencies among studies involving Par-
kin-deficient mice, we sought to determine whether there
were any functional consequences of Parkin-deficiency
following neurotoxic treatment with 6-OHDA or METH.
Parkin-deficient mice were not more sensitive to 6-OHDA
neurotoxicity. Specifically, the dose-dependent, behavio-
ral response to 6-OHDA treatment was indistinguishable
between WT and KO mice. Moreover, because APO-
induced rotational behavior reflects dopamine-receptor
supersensitivity [49,50], our results suggest that the com-
pensatory mechanisms underlying this phenomenon are
intact in Parkin-deficient mice. Despite the dose-depend-
ent increase in APO-induced rotational behavior, we were
unable to detect a dose-dependent effect of 6-OHDA on
dopamine depletion, thereby supporting a role for varia-
bles other than the extent of dopamine depletion on APO-
induced rotation [49,50]. With regard to the role of Parkin
in 6-OHDA toxicity, it has been observed that overexpres-
sion of Parkin protects against 6-OHDA toxicity in some
cell culture models [31] but not in others [63]. Our resultsBMC Neuroscience 2005, 6:71 http://www.biomedcentral.com/1471-2202/6/71
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suggest that Parkin-deficiency in mice does not dramati-
cally affect the pathways involved in 6-OHDA neurotoxic-
ity.
We previously reported that locomotion following treat-
ment with AMPH, which is chemically related to METH, is
indistinguishable between WT and KO mice [16]; in this
study we demonstrate that there is no difference in METH-
induced hyperthermia. Previous studies have suggested
that mouse Parkin is involved in regulating dopaminergic
and glutamatergic neurotransmission [18]. Our pharma-
cological, behavioral, neurochemical, and toxicity studies
are not consistent with these findings [16]. It was also
shown that Parkin can protect dopamine neurons in a
cell-culture model of glutamate excitotoxicity [64]. Our
results indicate that this finding cannot be extended to
METH-related glutamate toxicity of dopaminergic neu-
rons in a Parkin-deficient mouse model [44,45]. It has
also been proposed that Parkin is involved in METH tox-
icity because Parkin-immunoreactive aggregates have
been observed [42] and levels of Parkin and Pael-R, a
putative target for Parkin-mediated ubiquitination, are
decreased following METH treatment [65]. We found that
Parkin was not essential for METH or 6-OHDA neurotox-
icity.
Although our results suggest that Parkin-deficiency in
young mice does not greatly modify susceptibility of
dopaminergic neurons to acute METH or 6-OHDA neuro-
toxicity, interpretation is complicated by our use of a
mixed genetic background. We cannot rule out the possi-
bility that strain differences in genes linked to the targeted
parkin allele may confer protection against toxicity specif-
ically in KO mice thereby masking an effect due to Parkin-
deficiency. For example, genes linked to parkin, such as
tumor necrosis factor (~13 cM), are known to modify METH
toxicity [66]. To avoid this complication, future work
should utilize coisogenic mice as controls, especially
when small differences between genotypes are detected.
Despite this potential confound, Parkin does not appear
to play a critical role in protection against METH or 6-
OHDA neurotoxicity in mice.
Our results do not rule out the possibility that Parkin-defi-
cient mice could be more sensitive to other neurotoxins
which have different mechanisms of action than METH or
6-OHDA. For example, Parkin-deficient mice could be
more sensitive to the neurotoxic effects of rotenone,
maneb, paraquat, MPTP, or genetic overexpression of
putative Parkin substrates, such as aminoacyl-tRNA syn-
thetase cofactor p38 [67]. Moreover, interpretation of our
results is limited by the specific neurotoxic regimens used
in our experiments and the nature of negative findings; we
cannot exclude the possibility that alternative METH or 6-
OHDA neurotoxic regimens could reveal a latent suscepti-
bility of Parkin-deficient mice to these agents. For exam-
ple, our study utilized an acute model of toxicity in young
mice; Parkin may protect dopaminergic neurons from
specific, chronic insults, particularly in aged mice. Identi-
fying conditions that precipitate parkinsonism specifically
in Parkin-deficient mice would increase the utility of this
model and could provide insight into the mechanism of
AR-JP.
Alternatively, despite the limitations of our study, the
findings that Parkin-deficient mice are not more sensitive
to METH or 6-OHDA could suggest that the absence of a
robust parkinsonian phenotype in Parkin-deficient mice
is not due to the lack of exposure to appropriate environ-
mental triggers. Parkin function in mice could be funda-
mentally different than in humans, or a redundant E3
ubiquitin-protein ligase, not found in humans, could exist
in mice. Therefore, additional studies are necessary to
understand why Parkin-deficient mice do not display
robust signs of parkinsonism.
Conclusion
Aged Parkin-deficient mice do not display signs consistent
with oxidative stress, ubiquitin dysfunction, or dopamine
neuron terminal degeneration. Moreover, 3-month-old
Parkin-deficient mice on a mixed B6;129 genetic back-
ground are not more sensitive to the acute neurotoxic
effects of METH or 6-OHDA.
Methods
Mice
Parkin-deficient mice, with a targeted deletion of parkin
exon 2 (Park2tm1Rpa/Park2tm1Rpa; KO), and wild-type con-
trol mice (Park2+/Park2+; WT) were obtained by crossing
Park2tm1Rpa/Park2+  mice on a mixed B6;129S4 genetic
background [16]. Twenty-two-month old, male mice were
used for analysis of aged tissue; 3-month old, male mice
were used for METH and 6-OHDA toxicity experiments.
Mice were housed in a specific-pathogen-free facility,
maintained on a 12-hr light cycle, housed in groups, and
provided with free access to water and food (5053, Lab-
Diet; Richmond, IN). All procedures adhered to the Guide
for the Care and Use of Laboratory Animals [68] and were
approved by the University of Washington Institutional
Animal Care and Use Committee.
6-OHDA treatment
Mice received a unilateral, intrastriatal injection of SAL or
a freshly prepared 6-OHDA solution (6-hydroxy-
dopamine hydrobromide; Sigma-Aldrich; St. Louis, MO)
using a stereotaxic surgical procedure [69,70]. 6-OHDA-
treated mice received either a 4 µg or 8 µg dose, and all
treatment preparations contained 0.02% ascorbic acid.
Injections were targeted to the central caudate putamen
using the following coordinates: 0.8 mm anterior toBMC Neuroscience 2005, 6:71 http://www.biomedcentral.com/1471-2202/6/71
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bregma, 2.0 mm lateral to bregma, and 3.6 mm ventral to
the skull surface. Treatments were administered in a vol-
ume of 2.0 uL at a rate of 0.5 uL/min; after the injection,
the needle was left in place for 5 min. Surgical treatments
were performed without knowledge of genotypes. Four-
teen and 15 days after surgery, rotational-behavior was
evaluated in response to APO (apomorphine hydrochlo-
ride hemihydrate; 0.5 mg/kg body weight subcutane-
ously; Sigma-Aldrich) or AMPH (D-amphetamine sulfate
salt; 2 mg/kg body weight intraperitoneally; Sigma-
Aldrich), respectively. Individual mice were acclimated in
a 16-cm diameter cylinder for 10 min. Mice were then
administered SAL (either subcutaneously or intraperito-
neally prior to APO or AMPH treatment, respectively),
and the number of complete clockwise or counter-clock-
wise rotations were observed for 30 min. Mice were then
administered either APO or AMPH and rotational behav-
ior was scored for an additional 30 min. Rotational behav-
ior was evaluated without knowledge of treatment or
genotype. Eighteen days after surgery, striatal tissue was
collected, as described [16], from both the injected and
intact sides to evaluate integrity of dopamine-neuron ter-
minals using neurochemical analyses.
METH treatment
Mice were administered repeated, intraperitoneal injec-
tions of SAL or METH ((+)-methamphetamine hydrochlo-
ride; Sigma-Aldrich) every 2 hr for a total of 4 injections.
METH-treated mice received either a low (2.5 mg/kg body
weight for each injection) or moderate (5.0 mg/kg) neu-
rotoxic regimen. Body temperature was monitored every
hour during METH treatment using a subcutaneously
implanted, programmable, temperature transponder (Bio
Medic Data Systems; Seaford, DE). Seven days after treat-
ment, striatal tissue was harvested to assess integrity of
dopamine-neuron terminals using neurochemical and
immunoblot analyses. Treatments were administered and
tissue was collected without knowledge of genotypes.
Neurochemical analyses
HPLC with electrochemical detection was used, as
described [16], to determine the striatal concentrations of
NE, dopamine, 5-HT, 3-MT, DOPAC, HVA, and 5-HIAA.
Analyses were conducted without knowledge of treatment
or genotype.
Immunoblot analyses
Protein lysates from dissected mouse brain tissue were
prepared by sonication in a solution containing 62.5 mM
Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate, 2% β-mer-
captoethanol, Complete Protease Inhibitor Cocktail
(Roche Diagnostics; Indianapolis, IN), and 1 mM phenyl-
methylsulfonyl fluoride. Samples were centrifuged
(15,000 × g, 10 min) and the supernatant was used for
immunoblot analysis. Protein (2 µg) was transferred to a
PVDF membrane (Hybond-P; Amersham Biosciences; Pis-
cataway, NJ) in duplicate using a slot-blot system (Bio-
Rad Bio-Dot SF; Hercules, CA). A slot-blot approach was
utilized because it enabled simultaneous analysis of a
large number of samples and unbiased normalization
using a fluorescent stain for total protein. For each sam-
ple, one replicate was subjected to immunoblot analysis,
and the other replicate was analyzed for total protein
using SYPRO Ruby Protein Blot stain (Molecular Probes;
Eugene, OR). Membranes were blocked with 5% milk in
TTBS (50 mM Tris-HCl, pH 7.5, 0.9% NaCl, 0.5%
Tween20) for 1 hr, incubated with primary antibody
diluted in blocking solution overnight (1:2000 rabbit
anti-ubiquitin, Dako, Carpinteria, CA; or 1:10000 rat anti-
DAT, Chemicon, Temecula, CA), washed 3 × 10 min in
TTBS, incubated with HRP-conjugated secondary antibod-
ies diluted in blocking solution for 1 hr (1:5000 anti-rab-
bit, Amersham Biosciences; 1:20000 anti-rat, Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA),
washed 3 × 10 min in TTBS, and developed using ECL Plus
(Amersham Biosciences, Piscataway, NJ). Blots were
scanned using the Storm 840 system and quantitated
using ImageJ (developed at the U.S. National Institutes of
Health and available on the Internet at http://
rsb.info.nih.gov/ij). Oxidatively modified proteins were
detected as described by Ballesteros et al. [71] using the
OxyBlot Kit (Chemicon).
Statistics
Data were analyzed using multi-way ANOVAs. Residuals
and homogeneity of variance were evaluated to ensure the
data met assumptions required for ANOVA. Data
obtained from the same mouse, for instance before and
after a treatment, were evaluated as a repeated measure.
Data are presented as mean ± SEM.
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